Overview

Open Label Extension Study of Bifeprunox

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer